Physician profile
Meaghan E Brown
NPI 1104296128
$1,970.25
in general payments reported to CMS, 2019-2025
25 companies · $614 in 2025
The $614 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.39 · 2022: $145 · 2023: $490 · 2024: $692 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,796.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $259.99 | 2023-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Amgen INC. | $233.85 | 2023-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $220.85 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $200.99 | 2021-2024 | Watchman, Bodyguardian |
| E.R. Squibb & Sons, L.L.C. | $181.21 | 2022-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.38 | 2024-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $99.36 | 2023-2025 | |
| Novo Nordisk INC | $74.08 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $57.07 | 2022-2023 | Verquvo |
| Inspire Medical Systems, INC. | $56.36 | 2023-2024 | Inspire |
| Janssen Pharmaceuticals, INC | $53.71 | 2024 | Xarelto |
| Daiichi Sankyo INC. | $51.00 | 2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $35.74 | 2023-2025 | Evkeeza |
| Altathera Pharmaceuticals LLC | $34.55 | 2024-2025 | Sotalol Hydrochloride |
| Lexicon Pharmaceuticals, INC. | $32.66 | 2023 | Inpefa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.67 | 2024-2025 | Jardiance |
| Medicomp INC | $30.15 | 2024 | Telepatch Cardiac Monitor |
| Amarin Pharma, INC. | $26.54 | 2022 | |
| Philips North America LLC | $24.30 | 2023 | |
| Abiomed | $23.43 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.73 | 2025 | |
| Cleerly, INC. | $20.16 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Medtronic, INC. | $15.73 | 2022 | |
| Kestra Medical Technology Services, INC. | $14.09 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $13.65 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meaghan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.